CLOV Quote, Financials, Valuation and Earnings

Centene has a net margin of -0.28% compared to Clover Health Investments's net margin of 2.81%. Clover Health Investments's return on equity of -7.67% beat Centene's return on equity of 12.65%.

Clover Health Investments has a consensus price target of $4.69, signalling upside risk potential of 32.04%. On the other hand Centene has an analysts' consensus of $78.16 which suggests that it could grow by 26.51%. Given that Clover Health Investments has higher upside potential than Centene, analysts believe Clover Health Investments is more attractive than Centene.

Clover Health Investments has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Centene has a beta of 0.478, suggesting its less volatile than the S&P 500 by 52.18%.

Clover Health Investments has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Centene offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clover Health Investments pays -- of its earnings as a dividend. Centene pays out -- of its earnings as a dividend.

Clover Health Investments quarterly revenues are $462.3M, which are smaller than Centene quarterly revenues of $46.6B. Clover Health Investments's net income of -$1.3M is lower than Centene's net income of $1.3B. Notably, Clover Health Investments's price-to-earnings ratio is -- while Centene's PE ratio is 9.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clover Health Investments is 1.18x versus 0.19x for Centene. Usually stocks with elevated PS ratios are considered overvalued.

Elevance Health has a net margin of -0.28% compared to Clover Health Investments's net margin of 4.47%. Clover Health Investments's return on equity of -7.67% beat Elevance Health's return on equity of 14.03%.

Clover Health Investments has a consensus price target of $4.69, signalling upside risk potential of 32.04%. On the other hand Elevance Health has an analysts' consensus of $505.44 which suggests that it could grow by 25.33%. Given that Clover Health Investments has higher upside potential than Elevance Health, analysts believe Clover Health Investments is more attractive than Elevance Health.

Clover Health Investments has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Elevance Health has a beta of 0.657, suggesting its less volatile than the S&P 500 by 34.296%.

Clover Health Investments has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Elevance Health offers a yield of 1.64% to investors and pays a quarterly dividend of $1.71 per share. Clover Health Investments pays -- of its earnings as a dividend. Elevance Health pays out 25.22% of its earnings as a dividend. Elevance Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Clover Health Investments quarterly revenues are $462.3M, which are smaller than Elevance Health quarterly revenues of $48.9B. Clover Health Investments's net income of -$1.3M is lower than Elevance Health's net income of $2.2B. Notably, Clover Health Investments's price-to-earnings ratio is -- while Elevance Health's PE ratio is 15.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clover Health Investments is 1.18x versus 0.51x for Elevance Health. Usually stocks with elevated PS ratios are considered overvalued.

Oscar Health has a net margin of -0.28% compared to Clover Health Investments's net margin of 9.04%. Clover Health Investments's return on equity of -7.67% beat Oscar Health's return on equity of 10.83%.

Clover Health Investments has a consensus price target of $4.69, signalling upside risk potential of 32.04%. On the other hand Oscar Health has an analysts' consensus of $19.43 which suggests that it could grow by 10.91%. Given that Clover Health Investments has higher upside potential than Oscar Health, analysts believe Clover Health Investments is more attractive than Oscar Health.

Clover Health Investments has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oscar Health has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Clover Health Investments has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oscar Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clover Health Investments pays -- of its earnings as a dividend. Oscar Health pays out -- of its earnings as a dividend.

Clover Health Investments quarterly revenues are $462.3M, which are smaller than Oscar Health quarterly revenues of $3B. Clover Health Investments's net income of -$1.3M is lower than Oscar Health's net income of $275.3M. Notably, Clover Health Investments's price-to-earnings ratio is -- while Oscar Health's PE ratio is 62.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clover Health Investments is 1.18x versus 0.48x for Oscar Health. Usually stocks with elevated PS ratios are considered overvalued.

Progyny has a net margin of -0.28% compared to Clover Health Investments's net margin of 4.65%. Clover Health Investments's return on equity of -7.67% beat Progyny's return on equity of 11.16%.

Clover Health Investments has a consensus price target of $4.69, signalling upside risk potential of 32.04%. On the other hand Progyny has an analysts' consensus of $26.25 which suggests that it could grow by 17.71%. Given that Clover Health Investments has higher upside potential than Progyny, analysts believe Clover Health Investments is more attractive than Progyny.

Clover Health Investments has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Progyny has a beta of 1.372, suggesting its more volatile than the S&P 500 by 37.195%.

Clover Health Investments has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Progyny offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clover Health Investments pays -- of its earnings as a dividend. Progyny pays out -- of its earnings as a dividend.

Clover Health Investments quarterly revenues are $462.3M, which are larger than Progyny quarterly revenues of $324M. Clover Health Investments's net income of -$1.3M is lower than Progyny's net income of $15.1M. Notably, Clover Health Investments's price-to-earnings ratio is -- while Progyny's PE ratio is 39.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clover Health Investments is 1.18x versus 1.73x for Progyny. Usually stocks with elevated PS ratios are considered overvalued.